John Overdeck’s Lipocine LPCN Stock Holding History

John Overdeck’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	84,887 +51,137	+152%	+$123K	﹤0.01%	4732
2026 Q1	$270K	Buy	+33,750	New	+$294K	﹤0.01%	4136
2023 Q3	–	Sell	-11,033	Closed	-$55.6K	–	3100
2023 Q2	$55.6K	Sell	11,033 -3,907	-26%	-$18.4K	﹤0.01%	2815
2023 Q1	$80.8K	Sell	14,940 -2,077	-12%	-$16K	﹤0.01%	2700
2022 Q4	$115K	Sell	17,017 -2,110	-11%	-$15.4K	﹤0.01%	2490
2022 Q3	$146K	Sell	19,127 -7,854	-29%	-$87.7K	﹤0.01%	2176
2022 Q2	$367K	Buy	26,981 +5,800	+27%	+$90.4K	﹤0.01%	1945
2022 Q1	$493K	Buy	21,181 +15,146	+251%	+$317K	﹤0.01%	2021
2021 Q4	$102K	Buy	+6,035	New	+$112K	﹤0.01%	4054
2020 Q3	–	Sell	-5,700	Closed	-$122K	–	3350
2020 Q2	$122K	Buy	+5,700	New	+$73.9K	﹤0.01%	2764
2019 Q2	–	Sell	-860	Closed	-$34K	–	3512
2019 Q1	$34K	Buy	+860	New	+$26.4K	﹤0.01%	2951

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $606M AUM

John Overdeck's LPCN Position: Q2 2026 in Review

John Overdeck increased its Lipocine (LPCN) stake by 152% in Q2 2026, buying an estimated $123K and bringing the position to 84,887 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

John Overdeck first reported a position in LPCN in Q1 2019 and has held it in 11 quarters since. The position peaked at $493K in Q1 2022. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

John Overdeck held 84,887 shares of Lipocine worth $217K as of Q2 2026.
John Overdeck bought 51,137 Lipocine shares in Q2 2026, an estimated $123K.
Lipocine made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4732 holding.
John Overdeck first reported a position in Lipocine in Q1 2019 and has held it in 11 quarters since.
John Overdeck's Lipocine position peaked at $493K in Q1 2022.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.